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Background
Viruses are obligate intracellular parasites, which must
exploit cellular pathways and specific factors to replicate.
Many fundamental discoveries were made studying inter-
actions between host and virus, including the discovery of
interferon, intrinsic immunity, oncogenes, mRNA splicing,
RNA interference, and tRNA retrograde transport in
human cells. Detailed knowledge of host-pathogen interac-
tions also fosters the development of new therapeutic stra-
tegies. Specific targeting of host factors has led to new
drugs to inhibit HIV-1 infection being introduced in the
clinic or about to enter clinical trials.
Methods
We performed chemical genetic screenings using libraries
of small molecules and HIV-1 vectors. Hits were identified
by at least two-fold inhibition of infection in the absence
of toxicity. Validation included dose-response curves,
assessment in primary cells with replication competent
HIV-1, target knock down, and isolation of escape mutant
viruses.
Results
The gyrase B inhibitor Coumermycin A1 (CA1) was a
confirmed hit, which inhibited HIV-1 replication by inde-
pendently targeting the viral capsid protein and Hsp90.
CA1 targeted a specific pocket in capsid, as determined by
mapping a viral escape mutant, isothermal titration calori-
metry and molecular docking. CA1 induced faster virus
uncoating, which resulted in lower accumulation of capsid
in the nucleus of infected cells and reduced integration
efficiency. Targeting of Hsp90 with CA1 impaired HIV-1
gene expression in acutely infected cells. Using chromatin
immunoprecipitation (ChIP) and immunofluorescence,
Hsp90 was found to migrate to the viral promoter. Hsp90
also mediated enhanced viral replication in conditions of
hyperthermia. Inhibition of Hsp90 specifically impaired
the NFkB pathway and prevented HIV-1 reactivation from
latency.
Conclusions
From a single hit in our screening, we have found that
HIV-1 capsid is a novel target influencing integration
efficiency, and that Hsp90 is a key mediator required for
HIV-1 gene expression and reactivation from latency.
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